All Pharma News
Chiesi champions new inhaler propellant to reduce carbon footprint

Chiesi champions new inhaler propellant to reduce carbon footprint
Phalguni Deswal PHARMACEUTICAL TECHNOLOGY
22 Apr 2024
Share Share
Chiesi Global Presents Long-Term Data on Treatment with Velmanase Alfa

Chiesi Global Presents Long-Term Data on Treatment with Velmanase Alfa
PR NEWSWIRE
08 Feb 2024
Share Share
Chiesi Group and Oak Hill Bio announce License and Development Agreement

Chiesi Group and Oak Hill Bio announce License and Development Agreement
BUSINESSWIRE
09 Jan 2024
Share Share
Chiesi Group and Oak Hill Bio announce License and Development Agreement

Chiesi Group and Oak Hill Bio announce License and Development Agreement
PR NEWSWIRE
08 Jan 2024
Share Share
Chiesi works with BBC to spread message about greener inhalers

Chiesi works with BBC to spread message about greener inhalers
Nick Paul Taylor FIERCE PHARMA
05 Dec 2023
Share Share
Chiesi Group signed a License Agreement with Haisco Pharmaceutical

Chiesi Group signed a License Agreement with Haisco Pharmaceutical
PR NEWSWIRE
20 Nov 2023
Share Share
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
PM LIVE
05 Sep 2023
Share Share
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group

Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
GLOBENEWSWIRE
31 Jul 2023
Share Share
Kindeva Drug Delivery, Chiesi Group, and H&T Presspart Team Up

Kindeva Drug Delivery, Chiesi Group, and H&T Presspart Team Up
CONTRACT PHARMA
19 Jul 2023
Share Share
Chiesi, Protalix`s Fabry disease approved as Elfabrio joins Fabrazyme

Chiesi, Protalix`s Fabry disease approved as Elfabrio joins Fabrazyme
Kyle LaHucik ENDPTS
10 May 2023
Share Share